Mark Kindy to Cathepsin B
This is a "connection" page, showing publications Mark Kindy has written about Cathepsin B.
Connection Strength
2.523
-
The cysteine protease cathepsin B is a key drug target and cysteine protease inhibitors are potential therapeutics for traumatic brain injury. J Neurotrauma. 2014 Mar 01; 31(5):515-29.
Score: 0.425
-
Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing A?PP containing the wild-type ?-secretase site sequence. J Alzheimers Dis. 2012; 29(4):827-40.
Score: 0.368
-
The cysteine protease inhibitor, E64d, reduces brain amyloid-? and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, ?-secretase activity. J Alzheimers Dis. 2011; 26(2):387-408.
Score: 0.343
-
Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease. Biol Chem. 2010 Aug; 391(8):861-72.
Score: 0.333
-
Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics. Biol Chem. 2007 Sep; 388(9):979-83.
Score: 0.272
-
Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders. Pharmacol Rev. 2022 07; 74(3):600-629.
Score: 0.190
-
GM6 Attenuates Alzheimer's Disease Pathology in APP Mice. Mol Neurobiol. 2019 Sep; 56(9):6386-6396.
Score: 0.151
-
Reduced Neuroinflammation and Improved Functional Recovery after Traumatic Brain Injury by Prophylactic Diet Supplementation in Mice. Nutrients. 2019 01 31; 11(2).
Score: 0.150
-
Brain pyroglutamate amyloid-? is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. J Alzheimers Dis. 2014; 41(1):129-49.
Score: 0.106
-
Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem Biophys Res Commun. 2009 Aug 21; 386(2):284-8.
Score: 0.077
-
Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. J Biol Chem. 2008 Mar 21; 283(12):7745-53.
Score: 0.070
-
Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease. Biochim Biophys Acta. 2012 Jan; 1824(1):89-104.
Score: 0.022
-
Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease. Biol Chem. 2007 Feb; 388(2):247-52.
Score: 0.016